Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 11.

Tomalik-Scharte, D; Fuhr, U; Hellmich, M; Frank, D; Doroshyenko, O; Jetter, A; Stingl, J C (2011). Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metabolism and Disposition, 39(5):927-932.

Abduljalil, K; Frank, D; Gaedigk, A; Klaassen, T; Tomalik-Scharte, D; Jetter, A; Jaehde, U; Kirchheiner, J; Fuhr, U (2010). Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clinical Pharmacology and Therapeutics, 88(5):643-651.

Jetter, A; Fätkenheuer, G; Frank, D; Klaassen, T; Seeringer, A; Doroshyenko, O; Kirchheiner, J; Hein, W; Schömig, E; Fuhr, U; Wyen, C (2010). Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antiviral Therapy, 15(7):975-983.

Tomalik-Scharte, D; Lütjohann, D; Doroshyenko, O; Frank, D; Jetter, A; Fuhr, U (2009). Plasma 4beta-Hydroxycholesterol: An Endogenous CYP3A Metric? Clinical Pharmacology and Therapeutics, 86(2):147-153.

Jetter, A; Kinzig, M; Rodamer, M; Tomalik-Scharte, D; Sörgel, F; Fuhr, U (2009). Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? European Journal of Clinical Pharmacology, 65(4):411-417.

Lück, H; Kinzig, M; Jetter, A; Fuhr, U; Sörgel, F (2009). Mesalazine pharmacokinetics and NAT2 phenotype. European Journal of Clinical Pharmacology, 64(1):47-54.

Doroshyenko, O; Fuhr, U; Kunz, D; Frank, D; Kinzig, M; Jetter, A; Reith, Y; Lazar, A; Taubert, D; Kirchheiner, J; Baum, M; Eisenbrand, G; Berger, F I; Bertow, D; Berkessel, A; Sörgel, F; Schömig, E; Tomalik-Scharte, D (2009). In vivo role of cytochrome P450 2E1 and glutathione-S-transferase activity for acrylamide toxicokinetics in humans. Cancer Epidemiology Biomarkers & Prevention, 18(2):433-443.

Muschler, E; Lal, J; Jetter, A; Rattay, A; Zanger, U; Zadoyan, G; Fuhr, U; Kirchheiner, J (2009). The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro. Basic & Clinical Pharmacology & Toxicology, 105(6):374-379.

Tomalik-Scharte, D; Doroshyenko, O; Kirchheiner, J; Jetter, A; Lazar, A; Klaassen, T; Frank, D; Wyen, C; Fätkenheuer, G; Fuhr, U (2008). No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. European Journal of Clinical Pharmacology, 64(10):1033-1035.

Klaassen, T; Jetter, A; Tomalik-Scharte, D; Kasel, D; Kirchheiner, J; Jaehde, U; Fuhr, U (2008). Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. European Journal of Clinical Pharmacology, 64(4):387-398.

Wyen, C; Fuhr, U; Frank, D; Aarnoutse, R E; Klaassen, T; Lazar, A; Seeringer, A; Doroshyenko, O; Kirchheiner, J C; Abdulrazik, F; Schmeisser, N; Lehmann, C; Hein, W; Schömig, E; Burger, D M; Fätkenheuer, G; Jetter, A (2008). Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clinical Pharmacology and Therapeutics, 84(1):75-82.

This list was generated on Mon Sep 25 12:29:57 2017 CEST.